Prot# 27955: A Randomized, Multicenter, Two-Arm, 12-Week Phase IIIb Study to Evaluate Quality of Life (QoL) Measures in Subjects with Relapsing Forms of Multiple Sclerosis Who are Transitioning From Rebif (Interferon beta-1a) to Rebif New Formulation (RNF